Anicom Holdings, Inc. (8715) AI Stock Analysis

• Market Cap: ¥60.74B
• Dividend Yield: 0.99%
• Average Volume (3M): 540.28K
• Price to Earnings (P/E): 22.2
• Beta (1Y): 0.78
• Revenue Growth: 10.37%
• EPS Growth: -3.77%
• Country: JP
• Employees: 933
• Sector: Financial
• Sector Strength: 70
• Industry: Insurance - Property & Casualty
• EPS (TTM): 8.69
• Shares Outstanding: 74,939,160
• 10 Day Avg. Volume: 414,860
• 30 Day Avg. Volume: 540,283
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,008.00
• Price Target Upside: 25.22% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 75 Outperform
• Price Target: ¥1,008.00 ▲(25.22% Upside)

Anicom Holdings, Inc. demonstrates strong financial performance, particularly in cash flow generation and revenue growth, which significantly boosts its overall score. Technical analysis indicates strong momentum, although caution is advised due to overbought signals. Valuation metrics suggest the stock may be overvalued, slightly tempering the overall score.

Anicom Holdings, Inc. Business Overview & Revenue Model

Company Description

Anicom Holdings, Inc., through its subsidiaries, provides pet insurance products and services in Japan. It offers animal hospital management, insurance agency, and paid employment placement services; and clinical research services in animal medicine field. In addition, the company plans, develops, and operates internet services related to pets. Anicom Holdings, Inc. was founded in 2000 and is based in Tokyo, Japan.

How the Company Makes Money

Anicom Holdings generates revenue primarily through its pet insurance services, which account for a significant portion of its income. The company sells various insurance policies that cover veterinary expenses, enabling pet owners to manage the costs associated with pet healthcare. Additionally, Anicom earns revenue from its veterinary clinics and hospitals, where it provides medical services, diagnostics, and treatments for pets. Partnerships with veterinary practices and pet product suppliers also contribute to its earnings by creating synergies that enhance service offerings and customer reach. Factors such as the increasing pet ownership rates, rising awareness of pet health, and a growing preference for pet insurance in Japan directly support the company's revenue growth.

Anicom Holdings, Inc. Financial Statement Overview

Summary

Anicom Holdings, Inc. presents a robust financial profile with strong revenue growth and profitability improvements. The balance sheet reflects a stable financial structure with manageable debt levels. Exceptional cash flow performance enhances the company's financial flexibility and resilience.

Income Statement

Anicom Holdings, Inc. has demonstrated strong revenue growth with a 35.2% increase in the latest year, indicating robust business expansion. The net profit margin improved to 5.37%, reflecting enhanced profitability. However, the EBIT margin decreased slightly, suggesting potential cost management challenges.

Balance Sheet

The company maintains a healthy debt-to-equity ratio of 0.36, indicating prudent financial leverage. The return on equity stands at 11.57%, showcasing effective utilization of shareholder funds. The equity ratio is solid, reflecting a stable financial position.

Cash Flow

Anicom Holdings, Inc. exhibits impressive free cash flow growth of 242.4%, highlighting strong cash generation capabilities. The operating cash flow to net income ratio of 1.36 indicates efficient cash conversion from earnings. The free cash flow to net income ratio of 0.91 further underscores the company's strong cash flow position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	65.83B	67.42B	60.33B	56.41B	52.81B	47.87B
Gross Profit	67.68B	67.42B	60.43B	56.41B	52.81B	47.87B
EBITDA	5.05B	4.79B	5.16B	4.53B	4.07B	3.35B
Net Income	3.25B	3.25B	2.73B	2.28B	2.11B	1.59B
Balance Sheet
Total Assets	72.49B	72.49B	66.36B	61.41B	58.63B	55.46B
Cash, Cash Equivalents and Short-Term Investments	26.46B	26.46B	23.88B	30.84B	29.64B	31.68B
Total Debt	10.00B	10.00B	5.00B	5.00B	5.00B	5.00B
Total Liabilities	44.42B	44.42B	36.21B	33.22B	31.32B	29.74B
Stockholders Equity	28.07B	28.07B	29.90B	28.18B	27.32B	25.71B
Cash Flow
Free Cash Flow	0.00	5.81B	4.83B	3.57B	3.24B	3.07B
Operating Cash Flow	0.00	6.40B	5.67B	4.42B	4.46B	4.23B
Investing Cash Flow	0.00	-5.09B	-11.13B	-4.07B	-5.49B	-2.13B
Financing Cash Flow	0.00	271.00M	-1.34B	-212.00M	-112.00M	5.15B

Anicom Holdings, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 805.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8715, the sentiment is Neutral. The current price of 805 is below the 20-day moving average (MA) of 880.45, below the 50-day MA of 829.34, and above the 200-day MA of 668.42, indicating a neutral trend. The MACD of -5.80 indicates Positive momentum. The RSI at 35.55 is Neutral, neither overbought nor oversold. The STOCH value of 3.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:8715.

Anicom Holdings, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7327	78 Outperform	367.22B	11.18	6.13%	3.07%	6.67%	51.21%
8715	75 Outperform	¥60.74B	22.21	―	0.99%	10.37%	-3.77%
8714	72 Outperform	176.30B	13.70	5.58%	2.19%	11.55%	10.91%
7167	71 Outperform	791.43B	14.32	―	1.76%	13.30%	40.85%
7326	65 Neutral	37.21B	18.15	―	1.53%	9.57%	56.23%
7157	64 Neutral	159.64B	25.40	6.51%	―	22.42%	5.10%
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%

Anicom Holdings, Inc. Corporate Events

Anicom Holdings Reports Growth in Pet Insurance and Advances in Regenerative Medicine

Anicom Holdings, Inc. has released its monthly management parameters for February 2025, highlighting its progress in the pet insurance sector and new business initiatives. The company reported an increase in net premiums written and the number of policies in force compared to the previous year. Additionally, Anicom is advancing its regenerative medicine business through the Research and Development Partnership for Animal Regenerative Medicine (PARM), which aims to standardize cell therapy services for domestic animals. The company is also promoting its BioInsurTech initiatives, focusing on preventing injuries and illnesses using big data.

Anicom Holdings Announces Treasury Share Cancellation

Anicom Holdings, Inc. has announced a decision to cancel a portion of its treasury shares, specifically 6,370,000 shares, which represents 7.83% of the total issued shares prior to cancellation. This move, set to take effect on March 31, 2025, will reduce the total number of issued shares to 74,939,160, potentially impacting shareholder value and market perception.

Anicom Holdings Completes Share Repurchase and Plans Future Capital Optimization

Anicom Holdings has completed a share repurchase as part of its capital policy, following a resolution from its Board of Directors. With a stable financial position and surplus capital, the company plans to continue optimizing capital efficiency and may consider further share repurchases in future fiscal years, while maintaining compliance with solvency regulations.

Anicom Holdings Reports Progress in Pet Insurance and New Initiatives

Anicom Holdings reported its management parameters for December 2024, detailing its progress in the pet insurance and new business sectors. The company recorded growth in net premiums written, an increase in the number of policies in force, and maintained a stable renewal rate. It also reported advancements in its regenerative medicine and BioInsurTech initiatives, with an increase in the number of PARM hospitals and patents held. These developments underscore Anicom’s strategic shift towards a prevention-oriented business model, aiming to enhance its market position and offer innovative healthcare solutions for pets.